Neuropsychiatric Drug Development
•84 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (84)
| Company | Market Cap | Price |
|---|---|---|
|
JNJ
Johnson & Johnson
CAPLYTA represents neuropsychiatric drug development, a distinct therapeutic area.
|
$492.05B |
$205.33
+0.50%
|
|
ABBV
AbbVie Inc.
AbbVie’s Neuroscience pipeline (e.g., Vyalev, Tavapadon, PIVEC) places it in Neuropsychiatric Drug Development.
|
$388.96B |
$223.91
+1.69%
|
|
BMY
Bristol-Myers Squibb Company
Cobenfy in schizophrenia drives Neuropsychiatric Drug Development as a focus area.
|
$108.00B |
$54.65
+2.99%
|
|
VTRS
Viatris Inc.
Effexor GAD in Japan indicates neuropsychiatric/ CNS drug development activity.
|
$14.42B |
$12.46
+0.69%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$13.49B |
$136.72
+0.54%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$13.37B |
$35.24
+30.33%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis has CNS-focused antisense programs and intrathecal delivery (e.g., SPINRAZA/QALSODY), placing it in Neuropsychiatric Drug Development.
|
$12.52B |
$81.17
+3.36%
|
|
JAZZ
Jazz Pharmaceuticals plc
Jazz's neuroscience and sleep/epilepsy programs (Xywav, Epidiolex) align with Neuropsychiatric Drug Development.
|
$10.58B |
$166.29
-4.64%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
CNS-targeted programs (MAPT, HTT, SNCA) place Arrowhead in Neuropsychiatric Drug Development space.
|
$8.83B |
$71.16
+11.40%
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's CNS/neuropsychiatric focus positions as Neuropsychiatric Drug Development.
|
$8.56B |
$170.90
-0.35%
|
|
PRAX
Praxis Precision Medicines, Inc.
CNS/neuropsychiatric drug development focus (epilepsy, essential tremor, DEEs).
|
$5.83B |
$270.86
-2.19%
|
|
INDV
Indivior PLC
Indivior’s focus on CNS/psychiatric conditions (opioid use disorder) aligns with Neuropsychiatric Drug Development.
|
$5.00B |
$36.17
-0.21%
|
|
ALKS
Alkermes plc
Neuropsychiatric drug development focus, including orexin-based and CNS disorders (narcolepsy programs).
|
$4.62B |
$28.79
+2.80%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's CNS focus spans multiple neuropsychiatric disorders (PDP, Rett, Alzheimer's disease psychosis, Lewy body dementia psychosis, essential tremor), aligning with neuropsychiatric drug development.
|
$4.41B |
$26.75
+2.29%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Crexont and Parkinson’s program align with Neuropsychiatric Drug Development / CNS therapeutics.
|
$3.99B |
$13.02
+2.40%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Fragile X Syndrome program (MRM-3379) aligns with neuropsychiatric/neurology drug development.
|
$3.80B |
$75.44
-0.17%
|
|
XENE
Xenon Pharmaceuticals Inc.
Pipeline includes Major Depressive Disorder (MDD) and Bipolar Depression (BPD), aligning with Neuropsychiatric Drug Development.
|
$3.22B |
$41.30
-1.16%
|
|
CNTA
Centessa Pharmaceuticals plc
Narcolepsy types 1 & 2 and idiopathic hypersomnia are neuropsychiatric sleep disorders, aligning with 'Neuropsychiatric Drug Development'.
|
$3.09B |
$22.89
-0.56%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus is focused on CNS/neuropsychiatric drug development with a pipeline spanning ADHD, depression, epilepsy, and Parkinson's disease, including SPN-817, SPN-820, and SPN-443.
|
$2.77B |
$49.09
-0.64%
|
|
DNLI
Denali Therapeutics Inc.
The company has CNS/neurodegenerative disease programs (ALS, Parkinson's readouts), aligning with neuropsychiatric drug development.
|
$2.34B |
$17.04
+6.37%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
Pipeline focuses on CNS/neuropsychiatric disorders (narcolepsy, Fragile X, DEEs), fitting Neuropsychiatric Drug Development.
|
$2.11B |
$36.65
-0.27%
|
|
AVDL
Avadel Pharmaceuticals plc
Narcolepsy and Idiopathic Hypersomnia lie in the CNS/neuropsychiatric space; Avadel is developing therapies in this area.
|
$2.09B |
$21.50
|
|
ZLAB
Zai Lab Limited
Neuropsychiatric drug development emphasis with KarXT for schizophrenia.
|
$1.99B |
$18.27
+1.00%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM anchors the company's growth in neuropsychiatric therapeutics (ADHD), aligning with neuropsychiatric drug development.
|
$1.44B |
$46.31
+1.38%
|
|
TSHA
Taysha Gene Therapies, Inc.
Rett syndrome involves CNS neurodevelopmental/neurological aspects, aligning with CNS therapeutic development.
|
$1.33B |
$5.24
+7.16%
|
|
BHVN
Biohaven Ltd.
OCD and other neuropsychiatric indications (e.g., MDD) place Biohaven in Neuropsychiatric Drug Development.
|
$1.05B |
$9.65
-2.77%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's pipeline centers on neuropsychiatric drug development, placing it in the Neuropsychiatric Drug Development investable theme.
|
$1.03B |
$13.36
-1.62%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
The portfolio includes neurodegenerative disease programs (PSP/Wolfram), aligning with 'Neuropsychiatric Drug Development' as a CNS-focused investable theme.
|
$1.02B |
$11.28
-0.97%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Rapport targets neurological and psychiatric disorders, aligning with neuropsychiatric drug development.
|
$1.00B |
$27.36
-0.58%
|
|
TBPH
Theravance Biopharma, Inc.
Theravance's lead neurology asset places it in Neuropsychiatric Drug Development / Neurology, reflecting its late-stage CNS/autonomic program.
|
$927.66M |
$18.11
-1.71%
|
|
ATAI
Atai Beckley N.V
Portfolio emphasizes neuropsychiatric drug development (e.g., TRD, SAD, CIAS), a key investable segment.
|
$919.51M |
$4.16
-3.03%
|
|
ARVN
Arvinas, Inc.
ARV-102 targets LRRK2 in the brain, placing the company in CNS/neurodegenerative drug development under the Neuropsychiatric Drug Development theme.
|
$820.07M |
$11.64
+4.21%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$804.36M |
$13.96
-9.73%
|
|
CMPS
COMPASS Pathways plc
Represents the company's focus on developing neuropsychiatric drugs in the CNS space.
|
$629.37M |
$6.86
+4.57%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$566.84M |
$91.70
+14.61%
|
|
VTYX
Ventyx Biosciences, Inc.
CNS-active small molecules with data in Parkinson's disease indicate neurodegenerative/neuropsychiatric drug development.
|
$557.63M |
$7.38
-5.69%
|
|
ZVRA
Zevra Therapeutics, Inc.
KP1077 targets IH and narcolepsy (neuropsychiatric/CNS indication), aligning with Neuropsychiatric Drug Development.
|
$468.17M |
$8.34
|
|
VNDA
Vanda Pharmaceuticals Inc.
Company's CNS/psychiatric drug development portfolio (Fanapt, HETLIOZ) and pipeline expansion align with Neuropsychiatric Drug Development.
|
$465.03M |
$8.08
+2.67%
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$447.58M |
$15.15
-8.35%
|
|
DMAC
DiaMedica Therapeutics Inc.
Acute ischemic stroke program places the company in the CNS/neurology therapeutic space.
|
$441.42M |
$8.67
+1.52%
|
|
PRTC
PureTech Health plc
Cobenfy (KarXT) relates to schizophrenia, aligning with neuropsychiatric drug development.
|
$429.19M |
N/A
|
|
CYBN
Cybin Inc.
Company's pipeline focuses on neuropsychiatric drug development (MDD, GAD) with CYB003/CYB004.
|
$413.12M |
$8.30
+1.53%
|
|
AVXL
Anavex Life Sciences Corp.
Pipeline includes schizophrenia and other neuropsychiatric indications, aligning with neuropsychiatric drug development.
|
$339.28M |
$4.04
+2.15%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
PIPE-307/M1R inhibitor in RRMS and MDD aligns with neuropsychiatric drug development.
|
$280.42M |
$9.57
-4.30%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$264.78M |
$1.61
-1.53%
|
|
ALEC
Alector, Inc.
Alector pursues neurodegenerative CNS therapies, spanning frontotemporal dementia and Alzheimer’s disease.
|
$161.94M |
$1.67
+4.37%
|
|
SAVA
Cassava Sciences, Inc.
Strategic focus on neuropsychiatric/CNS drug development including simufilam for CNS disorders.
|
$154.10M |
$3.23
+1.10%
|
|
RLMD
Relmada Therapeutics, Inc.
Sepranolone is a neuropsychiatric therapeutic targeting compulsivity disorders (e.g., Tourette Syndrome, Prader-Willi Syndrome).
|
$140.40M |
$4.06
-4.02%
|
|
SGMO
Sangamo Therapeutics, Inc.
Company's neurology-focused CNS programs (ST-503/ST-506) align with neurodegenerative/neurology therapeutics.
|
$132.75M |
$0.44
+1.09%
|
|
CAMP
CAMP4 Therapeutics Corporation
CNS/neuropsychiatric disease focus through SYNGAP1 program; relevant to neuropsychiatric drug development.
|
$120.76M |
$5.97
-0.25%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL and related CNS/neurodegenerative programs place the company in neuropsychiatric/CNS drug development.
|
$99.71M |
$6.26
+1.46%
|
|
CRVO
CervoMed Inc.
CNS-focused neurodegenerative therapeutics (DLB, FTD, stroke) place CRVO in Neuropsychiatric Drug Development.
|
$72.26M |
$7.55
-3.33%
|
|
CLNN
Clene Inc.
The company focuses on neurodegenerative diseases (ALS, MS), aligning with neuro/drug development in CNS indications.
|
$72.13M |
$7.22
|
|
MNOV
MediciNova, Inc.
Pipeline includes CNS/neurodegenerative indications (ALS, MS), aligning with neuropsychiatric drug development.
|
$67.68M |
$1.41
+1.81%
|
|
IMUX
Immunic, Inc.
MS and neurodegenerative/inflammatory CNS focus aligns with neuropsychiatric drug development.
|
$62.86M |
$0.61
-3.80%
|
|
ASRT
Assertio Holdings, Inc.
Sympazan is used for neuropsychiatric/neural conditions, aligning with Neuropsychiatric Drug Development.
|
$61.79M |
$9.73
+1.09%
|
|
ABVC
ABVC BioPharma, Inc.
ABVC's MDD and ADHD programs (ABV-1504, ABV-1505, ABV-1601) indicate a neuropsychiatric drug development focus.
|
$55.32M |
$2.26
-3.83%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$47.49M |
$2.37
-1.66%
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Cannabis-induced CNS effects relate to neuropsychiatric drug development, aligning with Neuropsychiatric Drug Development.
|
$46.43M |
$1.13
|
|
COSG
Cosmos Group Holdings Inc.
Patent filings include potential MS therapy, aligning with neurodegenerative/neuropsychiatric drug development.
|
$45.86M |
$0.00
|
|
INMB
INmune Bio, Inc.
TRD program in peripheral inflammation and anhedonia places the company in Neuropsychiatric Drug Development.
|
$39.61M |
$1.53
+2.68%
|
|
LPCN
Lipocine Inc.
LPCN 1154 is targeted for postpartum depression, placing Lipocine's CNS/neuropsychiatric programs under Neuropsychiatric Drug Development.
|
$39.56M |
$7.61
+4.25%
|
|
JUNS
Jupiter Neurosciences, Inc.
Neuropsychiatric Drug Development: CNS/inflammation targets and Parkinson's disease-focused trial plans.
|
$36.23M |
$1.02
-1.92%
|
|
ATHE
Alterity Therapeutics Limited
The company targets neurological conditions (neurodegenerative diseases) and CNS drug development, aligning with Neuropsychiatric Drug Development.
|
$34.58M |
$3.17
-2.46%
|
|
BTAI
BioXcel Therapeutics, Inc.
Company targets neuropsychiatric disorders with agitation therapies, fitting 'Neuropsychiatric Drug Development'.
|
$29.26M |
$2.04
-1.69%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$29.02M |
$4.30
+3.61%
|
|
AYTU
Aytu BioPharma, Inc.
ADHD and pediatric CNS-focused therapeutics place AYTU within the neuropsychiatric drug development space.
|
$28.74M |
$2.71
-6.55%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
MIRA's pipeline includes neuropsychiatric drug development for CNS indications (anxiety, cognitive decline), fitting 'Neuropsychiatric Drug Development'.
|
$28.41M |
$1.48
-1.01%
|
|
IGC
IGC Pharma, Inc.
Neuropsychiatric drug development focus ( agitation, sleep disturbances in Alzheimer's), a CNS/psychiatric therapeutic area.
|
$26.58M |
$0.29
-0.38%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$22.09M |
$0.71
-0.69%
|
|
SER
Serina Therapeutics, Inc.
Pipeline focused on neuropsychiatric/neurodegenerative CNS indications (Parkinson's and tardive dyskinesia) as evidenced by SER-252, SER-270, and SER-214 programs.
|
$21.32M |
$2.12
+1.92%
|
|
APLT
Applied Therapeutics, Inc.
The company is developing CNS and neurologic disease therapies (govorestat and related ARI programs), aligning with neuropsychiatric drug development.
|
$14.40M |
$0.10
+3.30%
|
|
SCNX
Scienture Holdings, Inc.
The pipeline includes CNS/neuropsychiatric targets, placing SCNX in Neuropsychiatric Drug Development territory.
|
$8.46M |
$0.53
+1.39%
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$6.45M |
$0.28
-3.65%
|
|
ALZN
Alzamend Neuro, Inc.
Company targets neuropsychiatric conditions (BD, MDD, PTSD) in addition to Alzheimer's, indicating neuropsychiatric drug development activity.
|
$6.44M |
$2.10
+2.20%
|
|
ADXN
Addex Therapeutics Ltd
Company focuses on neuropsychiatric and CNS disorders via allosteric modulation platforms, including schizophrenia and brain injury rehabilitation programs.
|
$6.36M |
$8.00
+3.63%
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$4.61M |
$2.01
+45.65%
|
|
OGEN
Oragenics, Inc.
ONP-002 targets CNS/traumatic brain injury and is positioned within neuropsychiatric/CNS therapeutic development.
|
$3.77M |
$0.95
+2.56%
|
|
SILO
Silo Pharma, Inc.
Neuropsychiatric Drug Development covers the PTSD/anxiety and CNS-targeted therapeutic focus described in SPC-15/SPU-16 programs.
|
$3.33M |
$0.37
+3.18%
|
|
BICX
BioCorRx Inc.
BioCorRx's pipeline includes neuropsychiatric/CNS-focused therapeutic development (opioid withdrawal, methamphetamine use disorder).
|
$1.95M |
$0.29
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.45M |
$5.21
-2.71%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
Preclinical work in Parkinson's disease models indicates involvement in neurodegenerative disease research (neuropsychiatric/neurology area).
|
$359547 |
$0.14
|
|
CMND
Clearmind Medicine Inc.
CMND's pipeline focuses on neuropsychiatric conditions, placing it in Neuropsychiatric Drug Development as an investable theme.
|
$247708 |
$2.43
-2.41%
|
|
NLSP
NLS Pharmaceutics AG
Pipeline includes sleep and neuropsychiatric indications (narcolepsy, hypersomnia, ADHD), aligning with Neuropsychiatric Drug Development.
|
$219816 |
$0.79
-58.24%
|
Loading company comparison...
Loading industry trends...
Loading research report...
